Roche’s Tecentriq approved as first immunotherapy drug for breast cancer
Source: https://ift.tt/2J3Y1up
The drug received accelerated approval for combination with Celgene’s Abraxane based on Phase III data. According to a study, PD-L1-positive patients account for 26 percent of TNBC patients overall.
Source: https://ift.tt/2J3Y1up
0 Comments